Ossama Tawfik Selected Research

Noninfiltrating Intraductal Carcinoma (DCIS)

1/2022	Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.
1/2020	BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression.
1/2017	NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer.
1/2017	Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions.
9/2015	Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
1/2002	Ploidy differences between hormone- and chemical carcinogen-induced rat mammary neoplasms: comparison to invasive human ductal breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ossama Tawfik Research Topics

Disease

48	Neoplasms (Cancer) 01/2020 - 01/2002
17	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2002
7	Prostatic Neoplasms (Prostate Cancer) 10/2020 - 02/2007
7	Inflammation (Inflammations) 03/2017 - 12/2010
6	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2022 - 01/2002
6	Carcinogenesis 12/2019 - 03/2006
6	Osteosarcoma (Osteogenic Sarcoma) 03/2017 - 01/2012
4	Ductal Carcinoma 01/2018 - 03/2006
4	Neoplasm Metastasis (Metastasis) 01/2017 - 07/2003
4	Carcinoma (Carcinomatosis) 01/2017 - 05/2010
4	Atherosclerosis 06/2012 - 03/2002
3	Adenocarcinoma 01/2020 - 08/2006
3	Squamous Cell Carcinoma of Head and Neck 01/2020 - 12/2017
3	Non-alcoholic Fatty Liver Disease 11/2011 - 01/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 12/2019
2	Necrosis 01/2019 - 05/2010
2	Angiofibroma 01/2018 - 10/2017
2	Triple Negative Breast Neoplasms 11/2017 - 06/2015
2	Lobular Carcinoma 04/2016 - 06/2012
2	Leiomyosarcoma 01/2015 - 09/2014
2	Retinoblastoma (Glioblastoma, Retinal) 01/2015 - 03/2006
2	Hyperplasia 09/2012 - 03/2006
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2012 - 02/2011
2	Lung Neoplasms (Lung Cancer) 08/2012 - 02/2011
2	Vascular Remodeling 06/2012 - 08/2011
2	Polyploidy 01/2004 - 02/2002
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 12/2020
1	Pathologic Complete Response 01/2020
1	Radiation Fibrosis Syndrome (Radiation Fibrosis) 01/2018

Drug/Important Bio-Agent (IBA)

21	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2006
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2006
13	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 09/2005
11	Estrogen ReceptorsIBA 01/2019 - 06/2007
8	Messenger RNA (mRNA)IBA 12/2019 - 09/2008
7	Estrogens (Estrogen)FDA Link 01/2019 - 01/2003
6	Hormones (Hormone)IBA 01/2020 - 01/2002
5	ErbB Receptors (EGF Receptor)IBA 01/2013 - 06/2007
4	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2013
4	Interleukin-6 (Interleukin 6)IBA 12/2017 - 05/2012
4	CytokinesIBA 01/2017 - 05/2007
3	human ERBB2 proteinIBA 01/2017 - 05/2010
3	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 10/2005
3	Bile Acids and Salts (Bile Acids)IBA 03/2016 - 10/2013
3	Phenobarbital (Luminal)FDA Link 09/2015 - 05/2010
3	Biological ProductsIBA 06/2015 - 05/2012
2	ParaffinIBA 01/2022 - 01/2019
2	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 12/2020 - 01/2017
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 10/2009
2	Phosphotransferases (Kinase)IBA 12/2019 - 03/2006
2	Aromatase InhibitorsIBA 01/2019 - 01/2017
2	Cyclin D1IBA 01/2018 - 03/2016
2	Vitamin D FDA LinkGeneric 03/2017 - 01/2012
2	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2017 - 08/2011
2	CalciumIBA 03/2017 - 06/2014
2	MineralsIBA 03/2017 - 03/2002
2	Progesterone FDA LinkGeneric 01/2017 - 01/2003
2	MicroRNAs (MicroRNA)IBA 01/2017 - 01/2013
2	CarcinogensIBA 03/2016 - 01/2002
2	transgelinIBA 06/2015 - 09/2014
2	AndrogensIBA 12/2014 - 07/2014
2	Androgen Receptors (Androgen Receptor)IBA 07/2014 - 05/2010
2	Retinoid X Receptors (Retinoid X Receptor)IBA 10/2012 - 01/2012
2	Calcitriol Receptors (Calcitriol Receptor)IBA 10/2012 - 01/2012
2	MucinsIBA 09/2012 - 01/2012
2	Carrier Proteins (Binding Protein)IBA 08/2012 - 10/2011
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 11/2011 - 12/2010
2	Thromboplastin (Tissue Factor)IBA 11/2011 - 05/2010
2	LDL Receptors (LDL Receptor)IBA 11/2011 - 01/2009
2	Platelet-Derived Growth FactorIBA 08/2011 - 01/2007
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 07/2011 - 02/2011
2	Pharmaceutical PreparationsIBA 07/2011 - 01/2002
2	Alanine Transaminase (SGPT)IBA 12/2010 - 05/2010
2	Cyclin D3IBA 01/2004 - 02/2002
1	Formaldehyde (Formol)FDA Link 01/2022
1	Growth Differentiation Factor 15IBA 10/2020
1	ChromatinIBA 01/2020
1	PhosphoserineIBA 01/2020
1	Penfluridol (Semap)IBA 01/2020
1	Prolactin Receptors (Prolactin Receptor)IBA 01/2020
1	Antipsychotic Agents (Antipsychotics)IBA 01/2020
1	ProlactinIBA 01/2020
1	IntegrinsIBA 01/2020
1	Matrix Metalloproteinase 16IBA 01/2020
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 12/2019
1	Histone DemethylasesIBA 12/2019
1	Oncogene Proteins (Oncogene Protein)IBA 01/2019
1	Hematoxylin (Haematoxylon)IBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2019
1	ruxolitinibIBA 01/2019
1	Mucin-1 (CA 15-3 Antigen)IBA 01/2019
1	Surface-Active Agents (Surfactants)IBA 01/2019
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2018
1	CarbonIBA 01/2018

Therapy/Procedure

11	Therapeutics 01/2020 - 07/2003
3	Radiotherapy 01/2018 - 10/2006
2	Injections 01/2020 - 12/2019
2	Segmental Mastectomy (Lumpectomy) 01/2017 - 04/2016
2	Drug Therapy (Chemotherapy) 01/2015 - 08/2012
1	Neoadjuvant Therapy 01/2020